MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys

[1]  R. Roth,et al.  Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys. , 1990, Brain : a journal of neurology.

[2]  R. Roth,et al.  Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions , 1989, Neuroscience.

[3]  J. Rinne,et al.  Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra , 1989, Annals of neurology.

[4]  R. Roth,et al.  Telencephalic Projections of the A8 Dopamine Cell Group , 1988, Annals of the New York Academy of Sciences.

[5]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[6]  J. Langston,et al.  An electron microscopic study of MPTP-induced inclusion bodies in an old monkey , 1988, Brain Research.

[7]  S. P. Hunt,et al.  Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea , 1988, Neuroscience.

[8]  D. German,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost? , 1988, Neuroscience.

[9]  C. Marsden,et al.  An immunohistochemical study of the acute and long-term effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in the marmoset , 1987, Neuroscience.

[10]  R. Roth,et al.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF , 1987, Brain Research.

[11]  M. Zigmond,et al.  Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  C. Markham,et al.  Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP , 1987, Brain Research.

[13]  R. Roth,et al.  Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. , 1987, Life sciences.

[14]  J W Langston,et al.  Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys , 1986, Annals of neurology.

[15]  T. Paolo,et al.  Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys , 1986, Brain Research.

[16]  B. A. Brooks,et al.  Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys , 1986, Neuroscience.

[17]  R. Roth,et al.  Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1986, Neuroscience Letters.

[18]  I. Mitchell,et al.  Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus , 1985, Neuroscience Letters.

[19]  Y. Stern,et al.  Intellectual changes in patients with MPTP‐induced parkinsonism , 1985, Neurology.

[20]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[21]  H. Pakkenberg,et al.  The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, The New England journal of medicine.

[22]  D. Jacobowitz,et al.  Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. , 1985, Life sciences.

[23]  C. Marsden,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.

[24]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[25]  B. Bogerts,et al.  A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. , 1983, Biological psychiatry.

[26]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[28]  L. Swanson,et al.  The projections of the ventral tegmental area and adjacent regions: A combined fluorescent retrograde tracer and immunofluorescence study in the rat , 1982, Brain Research Bulletin.

[29]  Y. Agid,et al.  Distribution of Catecholamines in the Ventral Mesencephalon of Human Brain, with Special Reference to Parkinson's Disease , 1981, Journal of neurochemistry.

[30]  J. Fallon,et al.  Catecholamine innervation of the basal forebrain IV. Topography of the dopamine projection to the basal forebrain and neostriatum , 1978, The Journal of comparative neurology.

[31]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[32]  J. Greenfield,et al.  THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.

[33]  H. Witzleben.  METHODS OF TREATMENT IN POSTENCEPHALITIC PARKINSONISM , 1944 .

[34]  R. Roth,et al.  Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys. , 1990, Progress in Brain Research.

[35]  D. Jacobowitz,et al.  N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey. , 1984, Psychopharmacology bulletin.

[36]  F E Bloom,et al.  Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. , 1978, Annual review of neuroscience.